GlassScriptPhysician profile
Erin Schwab
NPI 1952677031
$81,270.05
in general payments reported to CMS, 2019-2025
35 companies · $51K in 2025
The $51K reported for 2025 was more than what 97% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $52.03 · 2022: $626 · 2023: $951 · 2024: $29K · 2025: $51K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Consulting Fee: $13K · Travel and Lodging: $13K · Food and Beverage: $4,675 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,845.60 |
| Consulting Fee | $13,347.50 |
| Travel and Lodging | $12,540.66 |
| Food and Beverage | $4,675.45 |
| Education | $182.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $66,649.84 | 2022-2025 | Zynyz, Pemazyre, Pemazyre |
| Janssen Biotech, INC. | $9,298.35 | 2022-2025 | Rybrevant, Darzalex, Erleada |
| Taiho Oncology, INC. | $1,400.00 | 2024 | |
| Janssen Scientific Affairs, LLC | $848.40 | 2024-2025 | Akeega, Rybrevant, Erleada |
| Astrazeneca Pharmaceuticals LP | $519.47 | 2022-2025 | Enhertu, Lynparza |
| Pharmacyclics LLC, An Abbvie Company | $355.04 | 2022-2023 | Imbruvica, Epkinly |
| Pfizer INC. | $352.31 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $219.15 | 2022-2025 | Onivyde, Somatuline Depot |
| Abbvie INC. | $183.31 | 2024-2025 | |
| Amgen INC. | $149.30 | 2022-2025 | Imdelltra (Amg757), Lumakras, Xgeva |
| Adc Therapeutics America, INC. | $125.00 | 2022 | |
| Servier Pharmaceuticals LLC | $122.71 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $119.54 | 2021-2025 | Opdualag |
| Beigene USA, INC. | $111.44 | 2023 | Brukinsa |
| Daiichi Sankyo INC. | $103.23 | 2023-2025 | Enhertu, Datroway |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $75.53 | 2021-2023 | |
| Seagen INC. | $69.73 | 2022-2023 | Adcetris |
| Regeneron Healthcare Solutions, INC. | $67.90 | 2023-2024 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $64.87 | 2024-2025 | |
| Emd Serono, INC. | $51.99 | 2023-2024 | Bavencio |
| Coherus Oncology, INC. | $46.88 | 2023 | |
| Medtronic, INC. | $43.98 | 2025 | Osteocool Rf Ablation System |
| Gilead Sciences, INC. | $34.55 | 2023-2025 | Trodelvy |
| Sirtex Medical INC | $29.94 | 2023 | Sir-Spheres Microspheres |
| Pharmaessentia USA Corporation | $27.37 | 2025 | Besremi |
| Sobi, INC | $27.20 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.25 | 2024 | Fruzaqla |
| Astellas Pharma US INC | $21.50 | 2022 | |
| Glaxosmithkline, LLC. | $21.47 | 2023 | Ojjaara |
| Blueprint Medicines Corporation | $19.34 | 2024 | Ayvakit |
| Mirati Therapeutics, INC. | $18.80 | 2023 | Krazati |
| Foundation Medicine, INC. | $17.67 | 2022 | |
| Merck Sharp & Dohme LLC | $17.42 | 2023 | Keytruda |
| Astellas Pharma Global Development | $17.26 | 2023 | Xtandi |
| Eisai INC. | $13.31 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Schwab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.